

Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting

Novakand Pharma is issuing the following operational update today:

- New management appointed, with Thomas Olin as interim CEO and Björn Petersson as CFO
- New website launched on July 16, 2026
- The Board of Directors intends to call an extraordinary general meeting. The meeting is scheduled to be held in September with the following main items on the agenda
 - election of auditor
 - amendment of the Articles of Incorporation to allow for the necessary capital raising for the preparation of coming clinical study
 - reasons for and authorization of the aforementioned capital raising
 - resolution regarding the Nomination Committee

Detailed information regarding the extraordinary general meeting will be provided in the upcoming notice.

About Novakand Pharma AB (publ)

Novakand Pharma is a clinical stage biotechnology company developing a new class of small-molecule orphan drugs for cancer.

For more information:

Visit the company's website at www.novakand.com or contact ir@novakand.com

Attachments

[Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting](#)